AZD1222
viral vector vaccine for prevention of COVID-19
Press Enter · cited answer in seconds
0 sources
Summary
AZD1222 is a funded product[1]. AZD1222 is a type of COVID-19 vaccine[2], adenovirus-based vaccine[3], and vaccine candidate[4].
Key Facts
- Manufacturer: Oswaldo Cruz Foundation[5], Serum Institute of India[6], HALIX B.V.[7], Advent SRL[8], Merck KGaA[9], Vaccitech[10], AstraZeneca[11], SK Bioscience[12], JCR Pharmaceuticals[13]
- Developer: Jenner Institute[14], Oxford BioMedica[15], University of Oxford[16], Vaccines Manufacturing and Innovation Centre[17], Pall Corporation[18], Cobra Biologics (United Kingdom)[19], AstraZeneca[20]
- Route of administration: intramuscular injection[21]
- Significant event: phase I/II clinical trial[22], phase III clinical trial[23]
- Sponsor: AstraZeneca[24]
- Described by source: A Study of a Candidate COVID-19 Vaccine (COV001)[25], Investigating a Vaccine Against COVID-19[26], Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial[27], A phase III study to investigate a vaccine against COVID-19[28], A phase I/II to determine efficacy, safety and immunogenicity of a candidate COVID-19 vaccine[29]
- Official name: Vaxzevria[30]
- Vaccine for: COVID-19[31]
- Price: 4 US dollars[32], 1.78 euro[33]
- Clinical trial phase: phase III clinical trial[34]
- Announcement date: November 2020[35]
- Funder: Coalition for Epidemic Preparedness Innovations[36], Biomedical Advanced Research and Development Authority[37], Government of the United Kingdom[38], GAVI[39], Operation Warp Speed[40]
- Study type: interventional study[41]